Month: September 2022

Breaking News

Exclusive: HHS OIG Declines to Penalize Drug Manufacturers at This Time Over 340B Contract Pharmacy Restrictions

In Breaking, Federal, Pharma IndustrySeptember 30, 20222577 Views

The U.S. HHS Office of Inspector General has put off a decision on penalizing drug manufacturers that have placed restrictions on access to 340B discounts in the contract pharmacy setting, 340B Report has learned.

The U.S. Department of Health and Human Services Office of Inspector General (HHS OIG) has informed a bipartisan group of House lawmakers that the enforcement agency does not plan to impose civil monetary penalties against the drug makers

…

Groups Representing 340B Hospitals Praise Federal Court Decision Halting Deep Medicare Part B Cuts

In Federal, Judicial, Pharma Industry, RegulatorySeptember 29, 2022571 Views

Laura Gilcrest and Ted Slafsky

U.S. District Court for the District of Columbia building

The federal district court in Washington, D.C. has ordered the government to immediately begin to pay 340B hospitals at full rates for Medicare Part B covered drugs.

In a big victory for 340B hospitals, a federal judge in Washington, D.C. ruled yesterday that the government must immediately begin to pay 340B hospitals the full Medicare Part B drug payment rate for the remainder of calendar

…

Fallout from New York Times’s 340B Investigative Piece Continues as Local Media, Policymakers, and Community Weighs In

In Federal, Legislative, RegulatorySeptember 29, 2022625 Views

Sarah True and Ted Slafsky

A New York Times investigative story on the 340B program continues to garner attention both locally and nationally.

Shockwaves from the New York Times’ investigative piece on the alleged misuse of 340B savings by a Catholic health system in Richmond, Virginia continues to spread, as local news outlets and government leaders from all levels respond. The

…

What’s the Secret to 340B and Specialty Pharmacy Provider and Patient Engagement?

In Sponsored ContentSeptember 29, 2022241 Views

Manchin and Braun Call on HHS To Take Immediate Action Against Drug Manufacturers in Contract Pharmacy Battle

In Federal, Legislative, Pharma Industry, RegulatorySeptember 29, 2022325 Views

Laura Gilcrest

Senators Manchin (D-WV) and Braun (R-Ind.) are urging HHS to take action against drug manufacturers who have placed restrictions in the contract pharmacy setting.

Government health officials need to take immediate action to fully enforce the law against drug makers who are denying 340B drug discounts to providers who use contract pharmacies to dispense 340B-priced drugs, U.S. Senator Joe Manchin (D-W.VA.) and

…

CVS Moves to Dismiss New York AG’s Antitrust Suit That Alleges Monopolistic Behavior Related to Wellpartner

In Pharma Industry, StateSeptember 29, 2022187 Views

Laura Gilcrest

CVS has asked a New York state court to dismiss an antitrust lawsuit alleging that the chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner.

CVS Health Corp. has asked a New York state court to dismiss the state’s antitrust lawsuit alleging that the pharmacy chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner as a

…

Generic/OTC Drug Maker Owes Refunds to 340B Providers, HRSA Audit Shows

In Federal, Pharma Industry, RegulatorySeptember 29, 2022119 Views

Laura Gilcrest

HRSA released findings from its audit of drug company VistaPharm.

The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products

…

National Association of Community Health Centers Calls On Congress “To Move Urgently” To Tackle 340B Contract Pharmacy Impasse “Before It’s Too Late”

In Breaking, Federal, Judicial, Legislative, Pharma IndustrySeptember 28, 20221263 Views

Laura Gilcrest and Ted Slafsky

After the government’s Administrative Dispute Resolution panel dismissed its complaint against drug manufacturers, NACHC is calling for Congress to take urgent action to address the contract pharmacy impasse.

Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the

…

New York Times Front Page Story on 340B Program Causes Shockwaves

In Federal, Regulatory, Trade AssociationSeptember 27, 20221467 Views

Laura Gilcrest

The New York Times weekend front page story on Bon Secours Mercy Health System’s alleged misuse of the 340B program is creating a stir in the 340B community.

340B stakeholders are responding to a long investigative article in Saturday’s New York Times that accuses a Catholic health system of exploiting the 340B discount program at the expense of one of its inner-city hospitals to enrich its

…

340B HIV Providers Warn of “Drug Industry Disinformation Campaign”

In Pharma Industry, Research/Reports, Trade AssociationSeptember 27, 2022280 Views

Sarah True

Drug manufacturers’ true goal is to cripple the 340B program, says Shannon Stephenson, RWC-340B President and CEO of Cempa Community Cares.

Ryan White Clinics for 340B Access (RWC-340B), a national organization of 340B HIV/AIDS medical providers, has published a detailed rebuttal of several recently published articles criticizing the 340B program. RWC-340B accuses article authors—many of whom are supported by

…